PARAMUS, N.J., March 25, 2024 (GLOBE NEWSWIRE) — Starton Therapeutics Inc., (“Starton” or the “Company”), a clinical-stage biotechnology company focused on transforming standard-of-care therapies with proprietary continuous delivery technology, today announced that Pedro Lichtinger, Chairman and Chief Executive Officer of Starton Therapeutics, will present and host one-on-one meetings at the MedInvest Biotech & Pharma Investor and 23rd Annual Needham Virtual Healthcare Conferences. Details for the events are as follows:
Starton Therapeutics to Present at Upcoming MedInvest and Needham Conferences
